Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Company profile
Ticker
VIVO
Exchange
Website
CEO
John Kenny
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MERIDIAN DIAGNOSTICS INC
SEC CIK
Corporate docs
Subsidiaries
Meridian Bioscience Corporation • Meridian Life Science, Inc. • Meridian Bioscience Europe, s.r.l. • Meridian Bioscience Europe S.A. • Meridian Bioscience Europe B.V. • Meridian Bioscience UK Ltd. • Meridian Bioscience International Ltd. • Meridian Bioscience Beijing, LLC • Meridian Bioscience Canada, Inc. • Meridian Bioscience Israel Holding Ltd ...
IRS number
310888197
VIVO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Feb 23
10-Q
2023 Q1
Quarterly report
9 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Feb 23
Transcripts
VIVO
Earnings call transcript
2022 Q2
6 May 22
VIVO
Earnings call transcript
2022 Q1
4 Feb 22
VIVO
Earnings call transcript
2021 Q4
12 Nov 21
VIVO
Earnings call transcript
2021 Q3
6 Aug 21
VIVO
Earnings call transcript
2021 Q2
7 May 21
VIVO
Earnings call transcript
2021 Q1
5 Feb 21
VIVO
Earnings call transcript
2020 Q4
13 Nov 20
VIVO
Earnings call transcript
2020 Q3
7 Aug 20
VIVO
Earnings call transcript
2020 Q2
9 May 20
VIVO
Earnings call transcript
2020 Q1
7 Feb 20
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13D/A
Magnetar Financial LLC
3 Feb 23
4
Felicia Williams
31 Jan 23
4
Catherine Sazdanoff
31 Jan 23
4
John McCune Jr. Rice
31 Jan 23
4
John McIlwraith
31 Jan 23
4
Dwight E Ellingwood
31 Jan 23
4
Anthony P Bihl III
31 Jan 23
4
James M. Anderson
31 Jan 23
4
John P. Kenny
31 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm | 74.10 mm |
Cash burn (monthly) | 2.45 mm | (no burn) | 9.70 mm | (no burn) | 783.00 k | (no burn) |
Cash used (since last report) | 27.55 mm | n/a | 108.99 mm | n/a | 8.80 mm | n/a |
Cash remaining | 46.55 mm | n/a | -34.89 mm | n/a | 65.30 mm | n/a |
Runway (months of cash) | 19.0 | n/a | -3.6 | n/a | 83.4 | n/a |
Institutional ownership, Q1 2023
2.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 218 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 22.95 mm |
Total shares | 1.13 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 1.13 mm | $22.95 mm |
Magnetar Financial | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 23 | Julie Diana Smith | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 25,600 | 0.00 | 0 |
31 Jan 23 | Julie Diana Smith | Common Stock | Sale back to company | Dispose D | No | No | 0 | 32,708 | 0.00 | 0 |
31 Jan 23 | Julie Diana Smith | Common Stock | Grant | Acquire A | No | No | 0 | 2,648 | 0.00 | 32,708 |
31 Jan 23 | Julie Diana Smith | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 27.03 | 2,000 | 54.06 k | 0 |
31 Jan 23 | Tony Serafini-Lamanna | Common Stock | Sale back to company | Dispose D | No | No | 0 | 43,338 | 0.00 | 0 |
31 Jan 23 | Tony Serafini-Lamanna | Common Stock | Grant | Acquire A | No | No | 0 | 7,945 | 0.00 | 43,338 |
31 Jan 23 | Tony Serafini-Lamanna | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.12 | 11,669 | 176.44 k | 0 |
31 Jan 23 | Tony Serafini-Lamanna | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.52 | 12,107 | 187.90 k | 0 |
31 Jan 23 | Tony Serafini-Lamanna | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 27.03 | 4,000 | 108.12 k | 0 |
31 Jan 23 | Tony Serafini-Lamanna | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.4 | 10,000 | 194.00 k | 0 |